Evidence map›Paper›PMID 37638008›Full record

ArticleFrontiers in immunology2023

The complex HLA-E-nonapeptide in Behçet disease.

Ángel Luís Castaño-Núñez, Marco-Antonio Montes-Cano, José-Raúl García-Lozano, Norberto Ortego-Centeno, Francisco José García-Hernández, Gerard Espinosa, Genaro Graña-Gil, Juan Sánchez-Bursón, María Rosa Juliá, Roser Solans and 11 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 17 institutions in 1 country.

Ángel Luís Castaño-NúñezDepartment of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), Sevilla, Spain.
Marco-Antonio Montes-CanoDepartment of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), Sevilla, Spain.
José-Raúl García-LozanoDepartment of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), Sevilla, Spain.
Norberto Ortego-CentenoDepartment of Internal Medicine, Hospital Clínico San Cecilio, Granada, Spain.
Francisco José García-HernándezDepartment of Internal Medicine, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Gerard EspinosaDepartment Autoimmune Diseases, Hospital Universitari Clínic, Barcelona, Spain.
Genaro Graña-GilDepartment of Rheumatology, Complejo Hospitalario Universitario A Coruña, Coruña, Spain.
Juan Sánchez-BursónDepartment of Rheumatology, Hospital Universitario de Valme, Sevilla, Spain.
María Rosa JuliáDepartment of Immunology, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
Roser SolansDepartment of Internal Medicine, Autoimmune Systemic Diseases Unit, Hospital Vall d'Hebron, Universidad Autonoma de Barcelona, Barcelona, Spain.
Ricardo BlancoDepartment of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Ana-Celia Barnosi-MarínDepartment of Internal Medicine, Complejo Hospitalario Torrecárdenas, Almería, Spain.
Ricardo Gómez de la TorreDepartment of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain.
Patricia FanloDepartment of Internal Medicine, Hospital Virgen del Camino, Pamplona, Spain.
Mónica Rodríguez-CarballeiraDeparment of Internal Medicine, Hospital Universitari Mútua Terrassa, Terrassa, Spain.
Luis Rodríguez-RodríguezDepartment of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain.
Teresa CampsDepartment of Internal Medicine, Hospital Regional Universitario de Málaga, Málaga, Spain.
Santos CastañedaDepartment of Rheumatology, Hospital de la Princesa, IIS-Princesa, Madrid, Spain.
Juan-Jose Alegre-SanchoDepartment of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain.
Javier MartínInstituto de Parasitología y Biomedicina "López-Neyra", CSIC, PTS Granada, Granada, Spain.
María Francisca González-EscribanoDepartment of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), Sevilla, Spain.
Hospital Universitario Virgen del Rocío · ESComplejo Hospitalario Torrecárdenas · ESComplexo Hospitalario Universitario A Coruña · ESHospital Clínico San Carlos · ESHospital Regional Universitario de Málaga · ESHospital Universitari de Vic · ESHospital Universitario Central de Asturias · ESHospital Universitario de La Princesa · ESHospital Universitario de Valme · ESHospital Universitario Doctor Peset · ESHospital Universitario Son Espases · ESHospital Virgen del Camino · ESInstituto de Investigación Biosanitaria de Granada · ESInstituto de Parasitología y Biomedicina "López - Neyra" · ESMarqués de Valdecilla University Hospital · ESMútua Terrassa · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The knowledge of the aetiology of Behçet disease (BD), an immune-mediated vasculitis, is limited. HLA-B, mainly HLA-B51, and HLA-A molecules are associated with disease, but the ultimate cause of this association remains obscure. There is evidence that NK cells participate in the etiopathology of BD. NK cells have activator and inhibitor surface receptors, like the KIR and the NKG2 families. Classical HLA-class I molecules (A, B and C) are keys in the activity control of the NK because they are KIR ligands. Most NKG2 receptors bind HLA-E, which presents only nonapeptides derived from the signal peptide of other class-I molecules. Objective: This study investigates the contribution of the pair HLA-E and ligand, nonapeptide derived from the 3-11 sequence of the signal peptides of class I classical molecules, to the susceptibility to BD. Methods: We analyzed the frequency of the HLA-derivated nonapeptide forms in 466 BD patients and 444 controls and an HLA-E functional dimorphism in a subgroup of patients and controls. Results: In B51 negative patients, the frequency of VMAPRTLLL was lower (70.4% versus 80.0% in controls; P=0.006, Pc=0.04, OR=0.60, 95%CI 0.41-0.86), and the frequency of VMAPRTLVL was higher (81.6% versus 71.4% in controls; P=0.004, Pc=0.03, OR=1.78, 95%CI 1.20-2.63). In homozygosity, VMAPRTLLL is protective, and VMAPRTLVL confers risk. The heterozygous condition is neutral. There were no significant differences in the distribution of the HLA-E dimorphism. Discussion: Our results explain the association of BD with diverse HLA-A molecules, reinforce the hypothesis of the involvement of the NK cells in the disease and do not suggest a significant contribution of the HLA-E polymorphism to disease susceptibility.

Indexed as

Behcet SyndromeGiant Cell ArteritisGranulomatosis with PolyangiitisHLA-A AntigensHLA-E AntigensHumansHLA-A AntigensHLA-E AntigensBehçet diseaseclassical HLA Class I moleculesgene associationHLA-ENK cells

Identifiers

PMID37638008
PMCPMC10449640
OpenAlexW4385728458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.